AR016133A1 - Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria - Google Patents
Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoriaInfo
- Publication number
- AR016133A1 AR016133A1 ARP980103779A ARP980103779A AR016133A1 AR 016133 A1 AR016133 A1 AR 016133A1 AR P980103779 A ARP980103779 A AR P980103779A AR P980103779 A ARP980103779 A AR P980103779A AR 016133 A1 AR016133 A1 AR 016133A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- compounds
- heterocycle
- group
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
Se describe compuestos que fijan VLA-4. Ciertos de estos compuestos inhiben también la adhesion de leucocitos y, en particular, la adhesion de leucocitosmedida por VLA-4. Tales compuestos son utiles en el tratamiento de enfermedades inflamatorias enun paciente mamífero, por ejemplo un ser humano, tal como asmaenfermedad de Alzheimer, aterosclerosis, demencia por SIDA, diabetes, enfermedad inflamatoria del intestino, artritis reumatoide, transplante de tejido,metástasis tumoral e isquemia en elmiocardio. Los compuestos pueden ser administrados también para el tratamiento de enfermedades inflamatorias del cerebrotal como esclerosis multiple. Los compuestos descriptos pueden ser de la formula (I) en la cual: R1 está seleccionado del grupo que consiste de alquilo,alquilo sustituido, arilo, arilo sustituido, cicloalquilo, cicloalquilo sustituido, heterociclo, hetereociclo sustituido, heteroarilo y heteroarilo sustituido;R2 está seleccionado del grupo que consiste de hidrogeno, alquilo, cicloalquilo, cicloalquilo sustituido, cicloalquenilo, cicloalquenilo sustituido,heterociclo, heterociclo sustituido, alquilo sustituido, arilo, arilo sustituido, heteroarilo, heteroarilo sustituido y R1 y R2 junto con el átomo de nitrogenounido a R2 yel grupo S0(2), unido a R1 pueden formar un grupo heterociclico o un grupo heterocíclico sustituido; R3 está seleccionado del grupo que consistede hidrogeno, alquilo, alquilo sustituido, cicloalquilo, cicloalquilo sustituido, arilo sustituido, heteroarilo, heteroarilo sustituido, heterociclo sustituidoy cuando R2 no forma un grupo heterocíclico con R1, R2 y R3 junto con el átomo de nitrogeno unido a R2 y el átomo carbono unido a R3 pueden formar unheterocíclico o un grupo heterocíclico sustituido; R5 es -(CH2)x-Ar-R5 en la cual R5 está seleccionado del grupo que consiste de -O-Z-NR8R8 y -O-Z-R12 en lacual R8 y R8 están seleccionados independientmente del grupo que consiste de hidrogeno, alquilo, alquilo sustituido, cicloalquilo, cicloalquilo sustituido,heterociclo, heterociclo sustituido y en la cual R8 y R8están unidos para formar un heterociclo o un heterociclo sustituido, R12 está seleccionado del grupo
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90442497A | 1997-07-31 | 1997-07-31 | |
US5445397P | 1997-08-01 | 1997-08-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR016133A1 true AR016133A1 (es) | 2001-06-20 |
Family
ID=26733051
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP980103779A AR016133A1 (es) | 1997-07-31 | 1998-07-30 | Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria |
Country Status (18)
Country | Link |
---|---|
EP (3) | EP1452532A1 (es) |
JP (3) | JP4431717B2 (es) |
KR (1) | KR100639055B1 (es) |
CN (1) | CN1119340C (es) |
AR (1) | AR016133A1 (es) |
AT (2) | ATE236146T1 (es) |
AU (2) | AU740681B2 (es) |
BR (1) | BR9811598A (es) |
CA (2) | CA2290745C (es) |
DE (2) | DE69812890T2 (es) |
ES (1) | ES2221183T3 (es) |
IL (1) | IL133636A0 (es) |
NO (1) | NO20000413L (es) |
NZ (1) | NZ502578A (es) |
PL (1) | PL338521A1 (es) |
RU (1) | RU2220964C2 (es) |
TW (1) | TW533211B (es) |
WO (2) | WO1999006390A1 (es) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6903075B1 (en) | 1997-05-29 | 2005-06-07 | Merck & Co., Inc. | Heterocyclic amide compounds as cell adhesion inhibitors |
US6221888B1 (en) | 1997-05-29 | 2001-04-24 | Merck & Co., Inc. | Sulfonamides as cell adhesion inhibitors |
CA2291708A1 (en) * | 1997-05-29 | 1998-12-03 | Merck & Co., Inc. | Sulfonamides as cell adhesion inhibitors |
ATE256699T1 (de) * | 1997-05-30 | 2004-01-15 | Celltech Therapeutics Ltd | Entzündungshemmende tyrosin-derivate |
US6482849B1 (en) | 1997-06-23 | 2002-11-19 | Tanabe Seiyaku Co., Ltd. | Inhibitors of α4β1 mediated cell adhesion |
NZ502580A (en) * | 1997-07-31 | 2001-06-29 | Elan Pharm Inc | 4-amino-phenylalanine compounds which inhibit leukocyte adhesion mediated by VLA-4 |
US6197794B1 (en) * | 1998-01-08 | 2001-03-06 | Celltech Therapeutics Limited | Phenylalanine derivatives |
MY153569A (en) | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
US6329372B1 (en) | 1998-01-27 | 2001-12-11 | Celltech Therapeutics Limited | Phenylalanine derivatives |
AU3260399A (en) | 1998-02-26 | 1999-09-15 | Celltech Therapeutics Limited | Phenylalanine derivatives as inhibitors of alpha4 integrins |
US6521626B1 (en) | 1998-03-24 | 2003-02-18 | Celltech R&D Limited | Thiocarboxamide derivatives |
GB9811159D0 (en) | 1998-05-22 | 1998-07-22 | Celltech Therapeutics Ltd | Chemical compounds |
GB9811969D0 (en) | 1998-06-03 | 1998-07-29 | Celltech Therapeutics Ltd | Chemical compounds |
US6685617B1 (en) | 1998-06-23 | 2004-02-03 | Pharmacia & Upjohn Company | Inhibitors of α4β1 mediated cell adhesion |
GB9814414D0 (en) | 1998-07-03 | 1998-09-02 | Celltech Therapeutics Ltd | Chemical compounds |
US6337340B1 (en) * | 1998-08-14 | 2002-01-08 | Gpi Nil Holdings, Inc. | Carboxylic acids and isosteres of heterocyclic ring compounds having multiple heteroatoms for vision and memory disorders |
US6333340B1 (en) * | 1998-08-14 | 2001-12-25 | Gpi Nil Holdings, Inc. | Small molecule sulfonamides for vision and memory disorders |
US6339101B1 (en) * | 1998-08-14 | 2002-01-15 | Gpi Nil Holdings, Inc. | N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders |
GB9821061D0 (en) | 1998-09-28 | 1998-11-18 | Celltech Therapeutics Ltd | Chemical compounds |
GB9821222D0 (en) | 1998-09-30 | 1998-11-25 | Celltech Therapeutics Ltd | Chemical compounds |
GB9825652D0 (en) | 1998-11-23 | 1999-01-13 | Celltech Therapeutics Ltd | Chemical compounds |
GB9826174D0 (en) | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
US6479492B1 (en) | 1999-01-22 | 2002-11-12 | Elan Pharmaceuticals, Inc. | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
WO2000043372A1 (en) * | 1999-01-22 | 2000-07-27 | Elan Pharmaceuticals, Inc. | Acyl derivatives which treat vla-4 related disorders |
AU769741B2 (en) | 1999-01-22 | 2004-02-05 | Elan Pharmaceuticals, Inc. | Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by VLA-4 |
US6436904B1 (en) | 1999-01-25 | 2002-08-20 | Elan Pharmaceuticals, Inc. | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
EP1161416B1 (en) | 1999-03-01 | 2004-04-14 | Elan Pharmaceuticals, Inc. | Alpha-aminoacetic acid derivatives useful as alpha 4 beta 7 - receptor antagonists |
US6518283B1 (en) | 1999-05-28 | 2003-02-11 | Celltech R&D Limited | Squaric acid derivatives |
WO2001010837A1 (en) * | 1999-08-05 | 2001-02-15 | The Procter & Gamble Company | Multivalent sulfonamides |
US6534513B1 (en) | 1999-09-29 | 2003-03-18 | Celltech R&D Limited | Phenylalkanoic acid derivatives |
US6455539B2 (en) | 1999-12-23 | 2002-09-24 | Celltech R&D Limited | Squaric acid derivates |
AP2002002565A0 (en) | 1999-12-28 | 2002-06-30 | Pfizer Prod Inc | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases. |
US6143776A (en) * | 2000-02-02 | 2000-11-07 | Sunesis Pharmaceuticals, Inc. | Tosylproline analogs as thymidylate synthase inhibitors |
EA006424B1 (ru) * | 2000-03-27 | 2005-12-29 | Апплайд Резеч Системз Арс Холдинг Н.В. | Фармацевтически активные производные пирролидина |
PT1268418E (pt) * | 2000-03-27 | 2006-08-31 | Applied Research Systems | Derivados da pirrolidina farmacologicamente activos com inibidores bax |
JP2003531141A (ja) | 2000-04-17 | 2003-10-21 | セルテック アール アンド ディ リミテッド | エナミン誘導体 |
US6403608B1 (en) | 2000-05-30 | 2002-06-11 | Celltech R&D, Ltd. | 3-Substituted isoquinolin-1-yl derivatives |
US6545013B2 (en) | 2000-05-30 | 2003-04-08 | Celltech R&D Limited | 2,7-naphthyridine derivatives |
WO2002004426A1 (en) | 2000-07-07 | 2002-01-17 | Celltech R & D Limited | Squaric acid derivatives containing a bicyclic heteroaromatic ring as integrin antagonists |
WO2002010136A1 (en) | 2000-08-02 | 2002-02-07 | Celltech R & D Limited | 3-substituted isoquinolin-1-yl derivatives |
MY129000A (en) | 2000-08-31 | 2007-03-30 | Tanabe Seiyaku Co | INHIBITORS OF a4 MEDIATED CELL ADHESION |
DE10155075A1 (de) | 2001-11-09 | 2003-05-22 | Merck Patent Gmbh | Cyclische Sulfonamide |
MY140707A (en) | 2002-02-28 | 2010-01-15 | Mitsubishi Tanabe Pharma Corp | Process for preparing a phenylalanine derivative and intermediates thereof |
EA007328B1 (ru) * | 2002-03-28 | 2006-08-25 | Апплайд Резеч Системз Арс Холдинг Н. В. | Тиазолидинкарбоксамидные производные как модуляторы рецептора простагландина f |
TW200307671A (en) | 2002-05-24 | 2003-12-16 | Elan Pharm Inc | Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins |
TWI281470B (en) | 2002-05-24 | 2007-05-21 | Elan Pharm Inc | Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins |
SK50642005A3 (sk) * | 2003-01-24 | 2006-02-02 | Elan Pharmaceuticals, Inc. | Kompozícia na liečenie demyelizačných ochorení a paralýzy podávaním remyelizačných látok |
US20050074451A1 (en) * | 2003-06-25 | 2005-04-07 | Elan Pharmaceuticals, Inc. | Methods and compositions for treating rheumatoid arthritis |
EP1706399A1 (en) * | 2004-01-23 | 2006-10-04 | Elan Pharmaceuticals, Inc. | Polyethylene glycol conjugates of heterocycloalkyl carboxamido propanoic acids |
US8076352B2 (en) | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
US7767689B2 (en) | 2004-03-15 | 2010-08-03 | Ptc Therapeutics, Inc. | Carboline derivatives useful in the treatment of cancer |
KR20120073287A (ko) | 2004-03-15 | 2012-07-04 | 피티씨 테라퓨틱스, 인크. | 혈관형성을 억제하는데 유용한 카르볼린 유도체 |
US8076353B2 (en) | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Inhibition of VEGF translation |
CA2561164A1 (en) * | 2004-04-01 | 2005-10-20 | Elan Pharmaceuticals, Inc. | Steroid sparing agents and their use |
KR101273614B1 (ko) | 2004-07-08 | 2013-06-12 | 엘란 파마슈티칼스, 인크. | 중합체 부분을 포함하는 다가 vla―4 길항제 |
US8143257B2 (en) * | 2004-11-23 | 2012-03-27 | Ptc Therapeutics, Inc. | Substituted phenols as active agents inhibiting VEGF production |
IN266863B (es) | 2005-01-13 | 2015-06-10 | Gene Techno Science Co Ltd | |
WO2006127584A1 (en) * | 2005-05-20 | 2006-11-30 | Elan Pharmaceuticals, Inc. | Imidazolone phenylalanine derivatives as vla-4 antagonists |
BRPI0616643A2 (pt) | 2005-09-29 | 2011-06-28 | Elan Pharm Inc | compostos de carbamato que inibem a adesão leucocitária mediada por vla-4 |
AU2006297220B8 (en) | 2005-09-29 | 2013-01-31 | Elan Pharmaceuticals, Inc. | Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by VLA-4 |
EP1996559A1 (en) | 2006-02-27 | 2008-12-03 | Elan Pharmaceuticals Inc. | Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by vla-4 |
WO2008007804A1 (fr) * | 2006-07-12 | 2008-01-17 | Gene Techno Science Co., Ltd. | ANTICORPS ANTI-INTÉGRINE α-9 HUMAINE ET UTILISATION DE CELUI-CI |
EP2124996A4 (en) | 2007-02-20 | 2010-03-24 | Merrimack Pharmaceuticals Inc | METHODS OF TREATING MULTIPLE SCLEROSIS BY ADMINISTERING ALPHA-FETOPROTEIN COMBINED WITH INTEGRIN ANTAGONIST |
WO2009126920A2 (en) | 2008-04-11 | 2009-10-15 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
EP3008056B8 (en) * | 2013-06-11 | 2021-03-03 | Receptos Llc | Novel glp-1 receptor modulators |
SG11201704532VA (en) * | 2014-12-12 | 2017-07-28 | Commw Scient Ind Res Org | Dislodgement and release of hsc from the bone marrow stem cell niche using alpha9 integrin antagonists |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6248713B1 (en) * | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
EP0917878A4 (en) * | 1997-02-26 | 2004-05-19 | Toray Industries | REMEDIES FOR HEPATITIS |
-
1998
- 1998-07-30 AR ARP980103779A patent/AR016133A1/es unknown
- 1998-07-31 CA CA002290745A patent/CA2290745C/en not_active Expired - Fee Related
- 1998-07-31 NZ NZ502578A patent/NZ502578A/en unknown
- 1998-07-31 AU AU85849/98A patent/AU740681B2/en not_active Ceased
- 1998-07-31 WO PCT/US1998/015324 patent/WO1999006390A1/en active IP Right Grant
- 1998-07-31 AT AT98937310T patent/ATE236146T1/de not_active IP Right Cessation
- 1998-07-31 RU RU2000104850/04A patent/RU2220964C2/ru not_active IP Right Cessation
- 1998-07-31 EP EP04011786A patent/EP1452532A1/en not_active Withdrawn
- 1998-07-31 AU AU86050/98A patent/AU8605098A/en not_active Abandoned
- 1998-07-31 EP EP98937052A patent/EP1000051B1/en not_active Expired - Lifetime
- 1998-07-31 ES ES98937052T patent/ES2221183T3/es not_active Expired - Lifetime
- 1998-07-31 WO PCT/US1998/015958 patent/WO1999006391A1/en active IP Right Grant
- 1998-07-31 EP EP98937310A patent/EP0954519B1/en not_active Expired - Lifetime
- 1998-07-31 CA CA002267175A patent/CA2267175C/en not_active Expired - Fee Related
- 1998-07-31 CN CN98807770A patent/CN1119340C/zh not_active Expired - Fee Related
- 1998-07-31 DE DE69812890T patent/DE69812890T2/de not_active Expired - Fee Related
- 1998-07-31 PL PL98338521A patent/PL338521A1/xx unknown
- 1998-07-31 AT AT98937052T patent/ATE267188T1/de not_active IP Right Cessation
- 1998-07-31 DE DE69824007T patent/DE69824007T2/de not_active Expired - Lifetime
- 1998-07-31 IL IL13363698A patent/IL133636A0/xx unknown
- 1998-07-31 KR KR1020007000952A patent/KR100639055B1/ko not_active IP Right Cessation
- 1998-07-31 BR BR9811598-7A patent/BR9811598A/pt not_active Application Discontinuation
- 1998-07-31 JP JP2000505149A patent/JP4431717B2/ja not_active Expired - Fee Related
- 1998-07-31 JP JP11511273A patent/JP2001502361A/ja active Pending
- 1998-07-31 TW TW087112594A patent/TW533211B/zh not_active IP Right Cessation
-
2000
- 2000-01-27 NO NO20000413A patent/NO20000413L/no not_active Application Discontinuation
-
2009
- 2009-08-07 JP JP2009185319A patent/JP2009269924A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR016133A1 (es) | Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria | |
AR014903A1 (es) | Compuestos del tipo 4-amino-fenilalanina inhibidores de la adhesion de leucocitos intermediada por vla-4, compuesto que son droga de dichos compuestos,composiciones farmaceuticas, metodo para adherir vla-4 en una muestra biologica, metodo para tratar una condicion inflamatoria | |
AR016387A1 (es) | Compuestos que inhiben la adhesion de leucocitos intermediada por vla-4, metodo para adherir vla-4 en una muestra biologica, composicion farmaceutica,metodo de tratamiento con dichos compuestos | |
JP6027095B2 (ja) | 置換されたジアミノカルボキサミドおよびジアミノカルボニトリルピリミジン、その組成物、ならびに、それを用いた治療方法 | |
CN1850779B (zh) | β-榄香烯含氮衍生物及其制备方法和用途 | |
KR20100099116A (ko) | 리버스턴 유사체의 신규 화합물 및 그의 용도(2) | |
KR900006300A (ko) | 피리미딘디온 유도체, 이것의 제조방법 및 이것을 함유한 항부정맥제 | |
EP3807251B1 (en) | Phenyl and pyridinyl substituted imidazoles as modulators of roryt | |
TNSN97127A1 (fr) | Derives de benzylamine amido-substitues, leurs derives precurseurs de medicaments, leur procede de preparation, compositions pharmaceutiques les contenant et methode de traitement les utilisant | |
UA56315C2 (uk) | Платиновий комплекс, спосіб його одержання, комплекс включення платинового комплексу, спосіб його одержання та фармацевтична композиція | |
HUP0402088A2 (hu) | Szubsztituált piperazin és piperidin vegyületek, az ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk a zsírsav-oxidáció gátlására használható gyógyszerkészítmények előállítására | |
FR2800735B1 (fr) | Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation | |
KR102325454B1 (ko) | 방사성표지화를 위한 방법 및 시약 | |
BR0007784A (pt) | Composto, método para inibir mudanças patológicas mediadas pela enzima que converte o tnf-alfa (tace) em um mamìfero, composição farmacêutica, e, processo para preparar um composto | |
DK319886D0 (da) | Kemiske forbindelser | |
RU2007141995A (ru) | 3,4-ДИГИДРОБЕНЗО[e], [1,3]ОКСАЗИН-2-ОНЫ | |
ES2110977T3 (es) | Espiro-isoquinolein-pirrolidinas y analogos de las mismas, utiles como inhibidores de la aldosa-reductasa. | |
CN1931869B (zh) | 5’-脱氧-5-氟胞苷类衍生物,它的制备方法及其用途 | |
EP0238883B1 (en) | Oxabicycloheptane derivatives, pharmaceutical composition and use | |
Silverman et al. | A mild method of hydrolysis of 2, 4-dialkoxy-6-substituted pyrimidines to 6-substituted uracils | |
WO2018213712A1 (en) | Pyrazoloquinazolinone antitumor agents | |
CA2708080A1 (en) | Antitumoral compounds | |
CN104804001B (zh) | 4‑取代吡咯并[2,3‑d]嘧啶化合物及其用途 | |
PT96123A (pt) | Metodo de preparacao de um medicamento para tratamento da infeccao do pneumocystis carinii | |
US3231564A (en) | p-chlorobenzyl 1-aziridine carbothioate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |